Cargando…

Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments

BACKGROUND: Xiezhuo Huayu Yiqi Tongluo Formula (XHYTF) consists of 14 Chinese herbal medicines. In this study, we investigated the potential mechanism of XHYTF in the treatment of uric acid nephropathy (UAN) through network pharmacology, molecular docking, and in vivo methods. METHODS: Using various...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Lifei, Guo, Yuqin, Wu, Qingmei, Hu, Tingting, Chen, Xiaomei, Guo, Jing, Liu, Ying, Lu, Yuhui, Lin, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974263/
https://www.ncbi.nlm.nih.gov/pubmed/36865745
http://dx.doi.org/10.1155/2023/6931644
_version_ 1784898690814574592
author Fan, Lifei
Guo, Yuqin
Wu, Qingmei
Hu, Tingting
Chen, Xiaomei
Guo, Jing
Liu, Ying
Lu, Yuhui
Lin, Min
author_facet Fan, Lifei
Guo, Yuqin
Wu, Qingmei
Hu, Tingting
Chen, Xiaomei
Guo, Jing
Liu, Ying
Lu, Yuhui
Lin, Min
author_sort Fan, Lifei
collection PubMed
description BACKGROUND: Xiezhuo Huayu Yiqi Tongluo Formula (XHYTF) consists of 14 Chinese herbal medicines. In this study, we investigated the potential mechanism of XHYTF in the treatment of uric acid nephropathy (UAN) through network pharmacology, molecular docking, and in vivo methods. METHODS: Using various pharmacological databases and analysis platforms, information on the active ingredients and targets of Chinese herbal medicine was collected, and UAN disease targets were retrieved using OMIM, Gene Cards, and NCBI. Then common target proteins were integrated. A Drug-Component-Target (D-C-T) map was constructed to screen core compounds and build a protein-protein interaction (PPI) network. Further, Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed for common targets, and a Drug-Component-Target-Pathway (D-C-T-P) network diagram was constructed. The molecular docking simulation was performed to verify the binding affinity between core components and hub targets. Subsequently, the UAN rat model was established, followed by the collection of serum and renal tissues. The expression levels of indicators in the serum were determined using an enzyme-linked immunosorbent assay. The pathological changes of renal tissues were detected using H & E staining and Masson staining. The expression of related proteins in renal tissue was detected by western blot. RESULTS: In the study, 216 active ingredients and 439 targets in XHYTF were screened, and 868 targets were identified as being related to UAN. Among them, 115 were common targets. Based on the D-C-T network, quercetin, luteolin, β-sitosterol, and stigmasterol were observed to be the key active ingredients of XHYTF that were effective against UAN. The analysis of the PPI network revealed TNF, IL6, AKT1, PPARG, and IL1β as the 5 key targets. GO enrichment analysis revealed that the pathways were mainly concentrated in cell killing, regulation of signaling receptor activity, and other activities. Subsequently, KEGG pathway analysis revealed that multiple signaling pathways, including the HIF-1, PI3K-Akt, IL-17, and other signaling pathways, were closely related to the action of XHYTF. All 5 key targets were confirmed to interact with all core active ingredients. In vivo experiments indicated that XHYTF significantly reduced blood uric acid and creatinine levels, alleviated inflammatory cell infiltration in kidney tissues, reduced the levels of serum inflammatory factors such as TNF-α and IL1β, and ameliorated renal fibrosis in rats with UAN. Finally, western blot revealed decreased levels of PI3K and AKT1 proteins in the kidney, which confirmed the hypothesis. CONCLUSION: Collectively, our observations demonstrated that XHYTF significantly protects kidney function, including alleviation of inflammation and renal fibrosis via multiple pathways. This study provided novel insights into the treatment of UAN using traditional Chinese medicines.
format Online
Article
Text
id pubmed-9974263
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-99742632023-03-01 Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments Fan, Lifei Guo, Yuqin Wu, Qingmei Hu, Tingting Chen, Xiaomei Guo, Jing Liu, Ying Lu, Yuhui Lin, Min Evid Based Complement Alternat Med Research Article BACKGROUND: Xiezhuo Huayu Yiqi Tongluo Formula (XHYTF) consists of 14 Chinese herbal medicines. In this study, we investigated the potential mechanism of XHYTF in the treatment of uric acid nephropathy (UAN) through network pharmacology, molecular docking, and in vivo methods. METHODS: Using various pharmacological databases and analysis platforms, information on the active ingredients and targets of Chinese herbal medicine was collected, and UAN disease targets were retrieved using OMIM, Gene Cards, and NCBI. Then common target proteins were integrated. A Drug-Component-Target (D-C-T) map was constructed to screen core compounds and build a protein-protein interaction (PPI) network. Further, Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed for common targets, and a Drug-Component-Target-Pathway (D-C-T-P) network diagram was constructed. The molecular docking simulation was performed to verify the binding affinity between core components and hub targets. Subsequently, the UAN rat model was established, followed by the collection of serum and renal tissues. The expression levels of indicators in the serum were determined using an enzyme-linked immunosorbent assay. The pathological changes of renal tissues were detected using H & E staining and Masson staining. The expression of related proteins in renal tissue was detected by western blot. RESULTS: In the study, 216 active ingredients and 439 targets in XHYTF were screened, and 868 targets were identified as being related to UAN. Among them, 115 were common targets. Based on the D-C-T network, quercetin, luteolin, β-sitosterol, and stigmasterol were observed to be the key active ingredients of XHYTF that were effective against UAN. The analysis of the PPI network revealed TNF, IL6, AKT1, PPARG, and IL1β as the 5 key targets. GO enrichment analysis revealed that the pathways were mainly concentrated in cell killing, regulation of signaling receptor activity, and other activities. Subsequently, KEGG pathway analysis revealed that multiple signaling pathways, including the HIF-1, PI3K-Akt, IL-17, and other signaling pathways, were closely related to the action of XHYTF. All 5 key targets were confirmed to interact with all core active ingredients. In vivo experiments indicated that XHYTF significantly reduced blood uric acid and creatinine levels, alleviated inflammatory cell infiltration in kidney tissues, reduced the levels of serum inflammatory factors such as TNF-α and IL1β, and ameliorated renal fibrosis in rats with UAN. Finally, western blot revealed decreased levels of PI3K and AKT1 proteins in the kidney, which confirmed the hypothesis. CONCLUSION: Collectively, our observations demonstrated that XHYTF significantly protects kidney function, including alleviation of inflammation and renal fibrosis via multiple pathways. This study provided novel insights into the treatment of UAN using traditional Chinese medicines. Hindawi 2023-02-21 /pmc/articles/PMC9974263/ /pubmed/36865745 http://dx.doi.org/10.1155/2023/6931644 Text en Copyright © 2023 Lifei Fan et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fan, Lifei
Guo, Yuqin
Wu, Qingmei
Hu, Tingting
Chen, Xiaomei
Guo, Jing
Liu, Ying
Lu, Yuhui
Lin, Min
Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments
title Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments
title_full Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments
title_fullStr Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments
title_full_unstemmed Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments
title_short Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments
title_sort mechanism of xiezhuo huayu yiqi tongluo formula in the treatment of uric acid nephropathy based on network pharmacology, molecular docking, and in vivo experiments
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974263/
https://www.ncbi.nlm.nih.gov/pubmed/36865745
http://dx.doi.org/10.1155/2023/6931644
work_keys_str_mv AT fanlifei mechanismofxiezhuohuayuyiqitongluoformulainthetreatmentofuricacidnephropathybasedonnetworkpharmacologymoleculardockingandinvivoexperiments
AT guoyuqin mechanismofxiezhuohuayuyiqitongluoformulainthetreatmentofuricacidnephropathybasedonnetworkpharmacologymoleculardockingandinvivoexperiments
AT wuqingmei mechanismofxiezhuohuayuyiqitongluoformulainthetreatmentofuricacidnephropathybasedonnetworkpharmacologymoleculardockingandinvivoexperiments
AT hutingting mechanismofxiezhuohuayuyiqitongluoformulainthetreatmentofuricacidnephropathybasedonnetworkpharmacologymoleculardockingandinvivoexperiments
AT chenxiaomei mechanismofxiezhuohuayuyiqitongluoformulainthetreatmentofuricacidnephropathybasedonnetworkpharmacologymoleculardockingandinvivoexperiments
AT guojing mechanismofxiezhuohuayuyiqitongluoformulainthetreatmentofuricacidnephropathybasedonnetworkpharmacologymoleculardockingandinvivoexperiments
AT liuying mechanismofxiezhuohuayuyiqitongluoformulainthetreatmentofuricacidnephropathybasedonnetworkpharmacologymoleculardockingandinvivoexperiments
AT luyuhui mechanismofxiezhuohuayuyiqitongluoformulainthetreatmentofuricacidnephropathybasedonnetworkpharmacologymoleculardockingandinvivoexperiments
AT linmin mechanismofxiezhuohuayuyiqitongluoformulainthetreatmentofuricacidnephropathybasedonnetworkpharmacologymoleculardockingandinvivoexperiments